Objective To compare the efficacy, safety and tolerability of Telmisartan combined with Hydrochlorothiazide (HCTZ) and Levamlodipine Besylate combined with HCTZ for isolated systolic hypertension in the elderly. Methods A total of 120 patients with systolic hypertension were randomly divided into two groups, with 60 cases in each group. The test group was treated with Telmisartan 40 mg q. D combined with HCTZ 12. 5 mg q. D. Those with poor antihypertensive efficacy were given another Telmisartan 40 mg q. D. The control group was treated with Levamlodipine Besylate 2.5 mg q. D combined with HCTZ 12. 5 mg q. D. Those with poor antihypertensive efficacy were given another Levamlodipine Besylate 2. 5 mg q. D. The course of treatment was 14 weeks in both groups. Results Results Markedly effective: test group 40 vs. Control group 24; effective; test group 20 vs. Control group 24; ineffective; test group 6 vs. Control group 12; cases of standard blood pressure: test group 54 vs. Control group 48; total effective rate; test group 90% vs. Control group 80% , P <0. 05. In test group, systolic pressure and mean arterial blood pressure reported significant differences after treatment (P < 0. 01) , while heart rate did not (P > 0. 05). In control group, systolic pressure, mean arterial systolic pressure and heart rate reported significant differences after treatment (P <0. 01). Systolic pressure of the two groups reported signifi-cant dinerence ( P < 0. 05 ). Inglycende and tasting blood sugar, which was significantly different from those in control group ( P < 0. 01) , reported significant differences after treatment compared with those before treatment ( P < 0. 05 ). Other biochemical indicators reported no statistic significance ( P > 0. 05 ). Adverse reaction in control group was significantly higher than that in test group (P < 0.01). Conclusion The antihypertensive efficacy of Telmisartan combined with HCTZ is better than that of Ijevamlodipine Besylate combined with HCTZ, which it is safe and well tolerated%目的 比较国产替米沙坦联合氢氛噻嗪(hydrochlorothiazide,HCTZ)与苯磺酸左旋氨氯地平联合HCTZ治疗老年单纯收缩期高血压(isolated systolic hypertension,ISH)的疗效、安全性及耐受性.方法 老年ISH患者120例采用随机数字表法分为试验组与对照组各60例.试验组给予替米沙坦40 mg联合HCTZ 12.5 mg口服,qd,降压不达标替米沙坦增加至80mg qd;对照组予苯磺酸左旋氨氯地平片2.5 mg联合HCTZ 12.5 mg口服,qd,降压不达标苯磺酸左旋氨氯地平增加至5 mg,qd,疗程均为14周.结果 ①显效:试验组40例,对照组24例;有效:试验组20例,对照组24例;无效:试验组6例,对照组12例;达目标血压的例数:试验组54例,对照组48例;总有效率:试验组90%,对照组80%.试验组总有效率高于对照组,差异有统计学意义(P<0.05).②试验组用药后收缩压、平均动脉压,与用药前比较,差异均有统计学意义(P<0.01),心率用药前后差异无统计学意义(P>0.05);对照组收缩压、平均动脉压、心率与用药前比较,差异均有统计学意义(P<0.01);两组用药后收缩压比较,差异有统计学意义(P<0.05).③试验组甘油三酯、空腹血糖与治疗前比较,差异有统计学意义(P<0.05),与对照组相比较,甘油三酯、空腹血搪差异有统计学意义(P<0.01),其余生化指标差异无统计学意义(P>0.05).④对照组不良反应发生率明显高于试验组,差异有统计学意义(P<0.01).结论 替米沙坦联合HCTZ降压疗效优于苯磺酸左旋氨氯地平联合氢氢噻嗪,并且安全性高,耐受性好.
展开▼
